Guggenheim Rates Septerna (SEPN) buy, $45 Price Target

Guggenheim reiterates its buy rating on Septerna, Inc. and sets a price target of $45.0, as the stock trades at $33.49, a 34.37% upside from the current price.

By TradeTexts Research Desk · Published Jul 1, 2026, 10:01 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Guggenheim rated Septerna, Inc. ($SEPN) "buy" with a $45 price target on July 1, 2026.

Since the rating, $SEPN is up 5.2% after 1 week, down 0.5% after 1 month and up 5.0% to date (from the $34.61 close on Jul 1, 2026).

SEPN Septerna, Inc.

$36.35 +29.91% year to date

Daily close · Oct 16, 2026

Key Points

On July 1, 2026, Guggenheim reiterated its buy rating on Septerna, Inc. with a new price target of $45.0, while the stock is currently at $33.49.
Septerna's stock has a 52-week range from $15.86 to $51.10, indicating significant potential upside based on the new target.
The average price target among analysts for Septerna, Inc. is $54.22, with a consensus rating of strong buy from nine analysts.

Get $SEPN trade alerts by text

We text you when insiders, Congress or big funds trade $SEPN. Free.

Not investment advice. TradeTexts is not a registered investment adviser, and this automated Septerna, Inc. alert may contain errors. Disclosures

Guggenheim Reiterates Buy Rating

On July 1, 2026, Guggenheim reiterated its buy rating on Septerna, Inc. (SEPN) with a price target of $45.0. The stock is currently trading at $33.49, showing a gap that suggests potential for growth. This rating comes as Septerna continues to make strides in the biotechnology sector, focusing on developing oral small molecule products.

Analysts Set New Price Targets

Guggenheim's new target reflects a positive outlook, especially with the stock trading well below its 52-week high of $51.10. Analysts have been bullish on Septerna, with several firms maintaining strong ratings. For instance, on August 19, 2026, JP Morgan maintained an Overweight rating with a target of $48.0, while Wells Fargo also kept its Overweight rating with a target of $50.0 on August 12, 2026. This reflects a consensus among analysts that Septerna has strong growth potential ahead.

Recent Insider Activity

Recent insider transactions show confidence in Septerna's prospects. On June 26, 2026, Shalini Sharp and L.P. Ra Capital Management each bought 15,000 shares. Though the average purchase price wasn't disclosed, these moves indicate that insiders believe in the company's future performance.

What Septerna, Inc. Does

Septerna, Inc., based in South San Francisco, is a clinical-stage biotechnology company focused on discovering and developing oral small molecule products. Their work primarily targets various diseases through G protein-coupled receptor (GPCR) mechanisms, which are crucial in many therapeutic areas, including endocrinology and immunology.

What to Watch at Septerna, Inc.

Investors should keep an eye on Septerna's next earnings report, scheduled for November 9, 2026. This will provide further insight into the company's performance and its potential to meet analyst expectations. Remember, the current analyst ratings and targets are based on data at the time of the reports and may not reflect the latest market conditions.

12-month forecast